查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1466354

吸入和鼻喷雾的学名药市场：按适应症、年龄层、药物类别、途径和分销管道 - 2024 年至 2030 年全球预测

Inhalation & Nasal Sprays Generic Drugs Market by Indication (Allergic Rhinitis, Asthma, COPD), Age Group (Adults, Children 2 to 5, Children 6 to 12), Class, Route, Distribution Channel - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

学名药药吸入和鼻喷雾市场规模预计到 2023 年为 80.9 亿美元，2024 年达到 87.8 亿美元，2030 年达到 144.3 亿美元，复合年增长率预计为 8.61%。

学名药吸入器和鼻喷雾是专利到期药物，与品牌药物具有生物等效性。学名药含有相同的活性成分，透过相同的给药途径给药，并旨在提供与品牌药相同的治疗效果。这些学名药通常是在品牌药的独占专利期结束后生产的，价格通常较低，因此可广泛用于治疗呼吸道疾病、过敏和其他鼻腔或肺部问题。吸入器和鼻喷雾的学名药市场主要是由呼吸系统疾病盛行率的增加、学名药的成本效益以及品牌药的专利到期的。此外，新兴市场的可近性提高以及对小病自我治疗的接受程度提高也有助于市场成长。然而，需要大量文件和临床试验的严格法律规范可能会延迟产品的商业化。来自品牌药物的竞争、有限的医疗预算和价格压力也是非专利药吸入器和鼻喷雾业务的主要障碍。儘管存在这些挑战，具有更好的给药系统和患者依从性方面的生物等学名药的研究和开发有望带来潜在的成长。医疗基础设施不断改善的新兴经济体为学名药药吸入器和鼻喷雾製造商提供了利润丰厚的机会。

主要市场统计
基准年[2023] 80.9亿美元
预测年份 [2024] 87.8亿美元
预测年份 [2030] 144.3亿美元
复合年增长率（%） 8.61%

适应症需要学名药来快速、即时缓解过敏性鼻炎症状

过敏性鼻炎是由于接触过敏原诱发IgE介导的发炎而引起的发炎疾病，并伴随打喷嚏、搔痒、鼻塞、流鼻水等症状。含有皮质类固醇和抗组织胺药物的学名药滴鼻剂喷剂被广泛用于控制和缓解这些症状。气喘是一种慢性发炎疾病，会导致气流阻塞和支气管痉挛。吸入性学名药（例如支气管扩张剂和吸入性皮质类固醇）对于治疗这种情况至关重要。慢性阻塞性肺病是一组以呼吸急促加剧为特征的进行性肺部疾病。支气管扩张剂、吸入性皮质类固醇和磷酸二酯酶 4 抑制剂等学名药用于吸入治疗 COPD。

年龄层：针对2至5岁儿童的产品开发不断增加

使用学名药吸入器和滴鼻剂的成年使用者通常会寻求气喘、慢性阻塞性肺病(COPD) 和过敏性鼻炎的治疗。对这一人群来说，药物疗效、使用便利性和成本效益是基于需求的偏好。儿童儿童，尤其是 2 至 5 岁的儿童，需要更安全、剂量更低且专门针对其年龄层的吸入器和鼻喷雾。儿童用配方通常更偏好并且具有适合年龄的递送机制。与年龄较小的儿童族群一样，6 至 12 岁的儿童需要安全的、儿童专用剂量的吸入器和滴鼻剂。然而，这个年龄层的儿童自我使用某些类型吸入器的能力越来越强，例如定量吸入器 (MDI)。

分销管道：提供有竞争力的价格和便利性的网路药局日益普及

医院医疗商店是取得学名药吸入器和滴鼻剂的重要中心，为住院患者提供即时，并为出院患者和就诊患者提供便利。这些商店主要满足紧急和急诊需求，其中即时给药至关重要。网路药局是一个不断成长的学名药分销管道，提供便利且价格往往具有竞争力。网路药局迎合了精通科技的消费者，他们重视自由裁量权，尤其是管理可能被污名化的疾病或需要定期长期用药的慢性病。对于需要吸入器和滴鼻剂等学名药的患者来说，零售药局是最常见、最方便的销售点。零售药局满足急性和慢性治疗需求，并且是快速取得的首选，特别是当线上交付时间表或医院地点不方便时。

区域洞察

美洲吸入器和鼻喷雾学名药市场受到包括慢性阻塞性肺病（COPD）和气喘在内的呼吸系统疾病的高盛行率、有利的报销政策和发达的医疗基础设施的推动，采用正在扩大。重磅吸入器的专利到期以及製造商之间的竞争加剧，使得学名药药的进入变得更便宜。美国肺臟协会等团体的努力也有助于提高人们对呼吸道疾病的认识，进一步增加对吸入器和鼻喷雾的需求。由于经济、监管和医疗保健环境的差异，欧洲、中东和非洲地区呈现多样化的市场动态。欧洲市场相对成熟，强调高品质的医疗保健，监管严格，有助于非专利药吸入和鼻喷雾市场的稳定成长。中东和非洲是具有巨大成长潜力的新兴市场。随着医疗保健成本的增加，成本控制措施推动了欧洲学名药的采用增加。在中东和非洲，医疗基础设施的改善和药物取得的增加正在推动市场成长。在非专利行业扩张和医疗保健成本上升的推动下，预计亚太地区学名药药吸入器和鼻喷雾市场的成长率最高。政府推广学名药的倡议以及製药公司建立生产设施也是亚太地区学名药药吸入器和鼻喷雾市场未来的积极指标。

FPNV定位矩阵

FPNV 定位矩阵对于评估学名药药吸入剂和鼻喷雾市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对学名药药吸入和鼻喷雾市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告对以下几个方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4. 竞争评估和情报：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1. 吸入器和鼻喷雾的学名药市场规模和预测是多少？

2.在学名药药吸入和鼻喷雾市场预测期内，有哪些产品、细分市场、应用和领域需要考虑投资？

3.吸入器和鼻喷雾学名药市场的技术趋势和法规结构是什么？

4.学名药药吸入/鼻喷雾市场主要供应商的市场占有率是多少？

5.进入吸入器和鼻喷雾学名药市场的适当型态和策略性手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 学名药成本低
      • 呼吸道疾病盛行率增加
      • 儿童用雾化器重要介绍
    • 抑制因素
      • 对学名药的严格监管
    • 机会
      • 重磅药物专利到期和 FDA核准增加
      • 药厂加大研发投入
    • 任务
      • 多个参与者的存在增加了价格压力
  • 市场区隔分析
    • 适应症：需要使用治疗过敏性鼻炎的学名药即时、立即缓解症状
    • 年龄层：加强2~5岁儿童产品研发
    • 分销管道：网路药局变得越来越受欢迎，因为它们提供有竞争力的价格和便利性。
  • 市场趋势分析
  • 俄罗斯-乌克兰衝突的累积影响
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法规结构分析
  • 客户客製化
    • 处方和给药装置的变更

第六章 吸入器和鼻喷雾的学名药市场

  • 过敏性鼻炎
  • 气喘
  • 慢性阻塞性肺病

第七章 吸入器和鼻喷雾的学名药市场：按年龄组

  • 成人
  • 2岁至5岁儿童
  • 6至12岁儿童

第八章吸入器和鼻喷雾的学名药市场：按类别

  • 过敏阻断剂
  • 抗胆碱能药
  • 抗组织胺药
  • 减充血剂
  • 肥大细胞抑制剂
  • 鼻类固醇

第九章 吸入器和鼻喷雾的学名药市场：按途径

  • 吸入
  • 鼻喷剂
  • 热带乳液

第十章吸入器和鼻喷雾的学名药市场：按分销渠道

  • 医院医疗用品店
  • 网路药房
  • 药局零售业

第十一章 美洲吸入器和鼻喷雾的学名药市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章 亚太地区吸入器和鼻喷雾学名药市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲吸入器和鼻喷雾学名药市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争场景分析
    • Usea Pharma 仿製药布非专利Budesonide获得美国FDA核准
    • Amphastar Pharmaceuticals 的盐酸纳洛酮鼻滴鼻剂4 毫克获得 FDA核准
    • Amneal 宣布其盐酸纳洛酮滴鼻剂（USP，4 mg）的简化新药申请已被美国FDA 受理

第15章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-032A67D9141A

[190 Pages Report] The Inhalation & Nasal Sprays Generic Drugs Market size was estimated at USD 8.09 billion in 2023 and expected to reach USD 8.78 billion in 2024, at a CAGR 8.61% to reach USD 14.43 billion by 2030.

Inhalation and nasal sprays generic drugs are off-patent pharmaceuticals that are bioequivalent to their branded counterparts. They contain the same active ingredients, are administered through the same route of administration, and are intended to have the same therapeutic effect as the original medications. These generic medications are often produced following the original drug's exclusive patent period and are typically offered at a lower cost, enabling wider accessibility to patients requiring treatment for respiratory conditions, allergies, and other nasal or pulmonary issues. The market for inhalation and nasal spray generic drugs is primarily driven by the increasing prevalence of respiratory diseases, the cost-effectiveness of generic products, and patent expiries of branded drugs. Enhanced accessibility in emerging markets and growing acceptance of self-medication for minor ailments also contribute to market growth. However, stringent regulatory frameworks that necessitate extensive documentation and clinical trials potentially delay product commercialization. Competition from branded drugs, limited healthcare budgets, and pricing pressures also pose significant hurdles for inhalation and nasal spray generic businesses. Despite the challenges, research and development in bioequivalent generic drugs with better delivery systems and patient compliance aspects promise potential growth. Developing economies with improving healthcare infrastructure present lucrative opportunities for generic inhalation and nasal spray generic drug manufacturers.

KEY MARKET STATISTICS
Base Year [2023] USD 8.09 billion
Estimated Year [2024] USD 8.78 billion
Forecast Year [2030] USD 14.43 billion
CAGR (%) 8.61%

Indication: Need for quick and immediate symptom relief generic medications for allergic rhinitis

Allergic rhinitis is an inflammatory condition caused by allergen exposure that triggers IgE-mediated inflammation, with symptoms such as sneezing, itching, nasal congestion, and rhinorrhea. Generic drugs in the form of nasal sprays, including corticosteroids and antihistamines, are widely used to manage and relieve these symptoms. Asthma, a chronic inflammatory disease, leads to airflow obstruction and bronchospasm. Inhalation of generic drugs, including bronchodilators and inhaled corticosteroids, are essential in the management of this condition. Chronic obstructive pulmonary disease is a group of progressive lung diseases characterized by increasing breathlessness. Generic medications, including bronchodilators, inhaled corticosteroids, and phosphodiesterase-4 inhibitors, are used inhaled to manage COPD.

Age Group: Increasing product development for children aged 2 to 5

Adult users of inhalation and nasal spray generic drugs commonly seek treatment for asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis. For this demographic, medication effectiveness, convenience of use, and cost-effectiveness are need-based preferences. The pediatric population, particularly those aged 2 to 5, require inhalation and nasal sprays that are safe, have a lower dosage, and are tailored specifically for their age group. Pediatric formulations are often designed to be more palatable and come with age-appropriate delivery mechanisms. Similar to the younger pediatric group, children aged 6 to 12 require inhalation and nasal sprays that are safe and specifically dosed for them. However, the capacity for children in this age bracket to manage certain inhaler types themselves, such as metered-dose inhalers (MDIs), increases.

Distribution Channel: Growing popularity of online pharmacies offering competitive pricing and convenience

Hospital medical stores are critical points of access for inhalation and nasal spray generic drugs, providing immediacy to in-patients and convenience to those being discharged or visiting for appointments. These stores primarily cater to the need for emergency care and acute treatments where the immediate administration of the medication is imperative. Online pharmacies represent a growing distribution channel for generic drugs, offering convenience and often competitive pricing. They cater to tech-savvy consumers who value discretion, particularly for conditions that may carry a stigma or for managing chronic conditions that require regular, long-term medication regimens. Retail pharmacies are the most common and accessible outlets for patients requiring inhalation and nasal spray generic drugs. They cater to both acute and chronic treatment needs and are a preferred choice for immediate access, especially when online delivery timelines or hospital locations are not convenient.

Regional Insights

The market for inhalation and nasal spray generic drugs in the Americas has been demonstrating growing adoption, with a high prevalence of respiratory disorders, including chronic obstructive pulmonary disease (COPD) and asthma, favorable reimbursement policies, and a well-established healthcare infrastructure. The entry of generic drugs has been supported by patent expirations of blockbuster inhalation drugs, intensifying competition among manufacturers and thus making medications more affordable. Initiatives by organizations, including the American Lung Association, also aid in increasing awareness about respiratory conditions, further driving the demand for inhalation and nasal sprays. The EMEA region exhibits diverse market dynamics owing to varying economic, regulatory, and healthcare environments. The European market is relatively mature, with a strong emphasis on high-quality healthcare and the presence of stringent regulations, contributing to a steady growth in the generic inhalation and nasal spray market. The Middle East and Africa present a nascent market with potential for significant growth. The rise in generic drug adoption in Europe is propelled by cost-containment measures amidst increasing healthcare costs. In the Middle East and Africa, improvements in healthcare infrastructure and increasing access to medicines are catalyzing market growth. The Asia-Pacific is anticipated to exhibit the highest growth rate in the inhalation and nasal spray generic drugs market, bolstered by an expanding generic industry, growing healthcare expenditure. Government initiatives to promote generic medications and the establishment of production facilities by pharmaceutical companies are also positive indicators for the future of the inhalation and nasal spray generic drugs market in APAC.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Inhalation & Nasal Sprays Generic Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Inhalation & Nasal Sprays Generic Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Inhalation & Nasal Sprays Generic Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Acerus Pharmaceuticals Corporation, Akorn, Inc., Altaire Pharmaceuticals Inc., Amphastar Pharmaceuticals, Inc., Apotex Inc., AptarGroup, Inc., AstraZeneca PLC, Beximco Pharmaceuticals Ltd., Catalent, Inc., Chiesi Farmaceutici S.p.A., Cipla Limited, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Mylan N.V., Nephron Pharmaceuticals Corporation, Nippon Shinyaku Co., Ltd., Padagis US LLC, Perrigo Company PLC, Preferred Pharmaceuticals, Inc., Recipharm AB, Sandoz International GmbH, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zhejiang Xianju Pharmaceutical Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Inhalation & Nasal Sprays Generic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Indication
    • Allergic Rhinitis
    • Asthma
    • COPD
  • Age Group
    • Adults
    • Children 2 to 5
    • Children 6 to 12
  • Class
    • Allergy Blocker
    • Anticholinergic
    • Antihistamine
    • Decongestant
    • Mast Cell Inhibitor
    • Nasal Steroid
  • Route
    • Inhalation
    • Nasal Spray
    • Tropical Lotion
  • Distribution Channel
    • Hospital Medical Store
    • Online Pharmacy
    • Pharmacy Retail
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Inhalation & Nasal Sprays Generic Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Inhalation & Nasal Sprays Generic Drugs Market?

3. What are the technology trends and regulatory frameworks in the Inhalation & Nasal Sprays Generic Drugs Market?

4. What is the market share of the leading vendors in the Inhalation & Nasal Sprays Generic Drugs Market?

5. Which modes and strategic moves are suitable for entering the Inhalation & Nasal Sprays Generic Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Low Cost Involved with Generic Prescription Drugs
      • 5.1.1.2. Increasing Prevalence of Respiratory Diseases
      • 5.1.1.3. Significant Adoption of Nebulizers for Children
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent Regulations For Generic Drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Patent Expiry of Blockbuster Drugs and Increasing FDA Approvals
      • 5.1.3.2. Growing Investments from Pharmaceutical Companies for R&D
    • 5.1.4. Challenges
      • 5.1.4.1. Pricing Pressure due to Presence of Multiple Players in the Segment
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Indication: Need for quick and immediate symptom relief generic medications for allergic rhinitis
    • 5.2.2. Age Group: Increasing product development for children aged 2 to 5
    • 5.2.3. Distribution Channel: Growing popularity of online pharmacies offering competitive pricing and convenience
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework Analysis
  • 5.9. Client Customization
    • 5.9.1. Changing Formulation & Delivery Device

6. Inhalation & Nasal Sprays Generic Drugs Market, by Indication

  • 6.1. Introduction
  • 6.2. Allergic Rhinitis
  • 6.3. Asthma
  • 6.4. COPD

7. Inhalation & Nasal Sprays Generic Drugs Market, by Age Group

  • 7.1. Introduction
  • 7.2. Adults
  • 7.3. Children 2 to 5
  • 7.4. Children 6 to 12

8. Inhalation & Nasal Sprays Generic Drugs Market, by Class

  • 8.1. Introduction
  • 8.2. Allergy Blocker
  • 8.3. Anticholinergic
  • 8.4. Antihistamine
  • 8.5. Decongestant
  • 8.6. Mast Cell Inhibitor
  • 8.7. Nasal Steroid

9. Inhalation & Nasal Sprays Generic Drugs Market, by Route

  • 9.1. Introduction
  • 9.2. Inhalation
  • 9.3. Nasal Spray
  • 9.4. Tropical Lotion

10. Inhalation & Nasal Sprays Generic Drugs Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Medical Store
  • 10.3. Online Pharmacy
  • 10.4. Pharmacy Retail

11. Americas Inhalation & Nasal Sprays Generic Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Inhalation & Nasal Sprays Generic Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Inhalation & Nasal Sprays Generic Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Eugia Pharma Gets USFDA Nod for Budesonide Generic
    • 14.3.2. Amphastar Pharmaceuticals Receives FDA Approval for Naloxone Hydrochloride Nasal Spray 4mg
    • 14.3.3. Amneal Announces U.S. FDA Filing Acceptance of Abbreviated New Drug Application for Naloxone Hydrochloride Nasal Spray, USP, 4mg

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET DYNAMICS
  • FIGURE 7. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COPD, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COPD, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CHILDREN 2 TO 5, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CHILDREN 2 TO 5, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CHILDREN 6 TO 12, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CHILDREN 6 TO 12, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ALLERGY BLOCKER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ALLERGY BLOCKER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ANTICHOLINERGIC, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ANTICHOLINERGIC, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ANTIHISTAMINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ANTIHISTAMINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DECONGESTANT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DECONGESTANT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY MAST CELL INHIBITOR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY MAST CELL INHIBITOR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY NASAL STEROID, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY NASAL STEROID, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY NASAL SPRAY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY NASAL SPRAY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY TROPICAL LOTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY TROPICAL LOTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY HOSPITAL MEDICAL STORE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY HOSPITAL MEDICAL STORE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PHARMACY RETAIL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PHARMACY RETAIL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 63. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 64. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 65. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 66. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 67. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 68. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 71. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 72. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 73. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 74. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 75. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 76. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 77. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 78. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 79. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 80. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 81. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 82. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 83. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 84. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 85. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 86. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 87. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 88. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 89. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 90. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 91. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 92. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 93. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 94. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 95. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 96. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 97. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 98. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 99. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 100. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 101. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 102. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 103. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 104. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 105. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 106. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 107. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 108. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 109. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 110. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 111. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 112. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 113. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 114. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 115. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 116. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 130. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 132. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 134. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 136. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 138. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 139. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 140. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 141. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 142. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 143. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 144. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 145. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 146. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 147. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 148. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 149. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 150. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 151. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 152. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 153. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 154. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 155. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 156. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 157. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 158. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 159. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 160. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 161. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 162. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 163. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 164. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 165. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 166. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 167. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 168. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 169. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 170. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 171. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 172. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 173. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 174. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 175. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 176. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 177. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 178. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 179. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 180. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 181. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 182. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 183. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 184. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 185. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 186. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 187. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 188. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 190. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 192. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 194. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 195. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 196. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 197. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 198. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 199. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 200. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 201. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 202. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 203. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 204. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 205. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 206. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 207. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 208. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 210. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 212. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 214. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 215. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 216. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 217. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 218. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 219. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 220. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 221. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 222. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 223. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 224. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 225. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 226. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 227. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 228. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 229. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 230. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 231. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 232. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 233. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 234. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 235. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 236. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 237. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 238. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 239. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 240. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 241. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 242. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 243. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 244. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 245. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 246. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 247. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 248. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 261. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 262. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 263. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 264. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 265. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 266. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 267. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 268. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 269. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 270. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 271. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 272. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 273. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 274. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 275. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 276. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 277. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 278. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 279. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 280. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 281. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 282. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 283. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 284. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 285. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 286. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 287. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 288. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 289. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 290. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRI